Melbourne (Australia) | 14 May 2024

Telix today announces three abstract presentations featuring the Company’s theranostic programs at the British Nuclear Medicine Society (BNMS) Annual Spring Meeting being held in Belfast, Northern Ireland this week.  

Today, Telix’s successful Phase III ZIRCON Study1 of TLX250-CDx (Zircaix®2 89Zr-DFO-girentuximab) in clear cell renal cell carcinoma will be featured in two presentations including a cutting-edge research Power Pitch highlights session.  

In addition, TLX66 (90Y-besilesomab), Telix’s investigational bone marrow conditioning therapy will be featured in an oral presentation by Gemma Lewis during the physics dosimetry session.  

BNMS presentation details are as follows:  

Title: Feasibility of single-timepoint imaging for organ dosimetry in [90Y]Anti-CD66 therapy 

Presenter: Gemma Lewis, Southampton General Hospital 

Date and Time: Tuesday, 14 May | 9:45 am – 10:00 am 

Session: Physics dosimetry abstracts 

Location: Room 1 

Title: Assessing Radiation Risks with 89Zr-girentuximab  

Presenter: Adnan Chowdhury, Royal Free Hospital 

Date and Time: Tuesday, 14 May | 10:30 am – 11:00 am 

Location: Exhibition Hall 

Title: 89Zr-DFO-girentuximab PET-CT imaging can accurately detect clear cell renal cell carcinoma primary and secondary lesions in patients with renal masses at conventional imaging, results from ZIRCON phase III study 

Presenter: Dr Thomas Wagner, Royal Free Hospital   

Date and Time: Tuesday, 14 May | 12:19 pm to 12:26 pm 

Session: Cutting edge research (including research power pitches) 

Location: Hall 2 

To register, please visit the website here.  

TLX250-CDx and TLX66 have not received a marketing authorisation in any jurisdiction.

  1. ClinicalTrials.gov ID: NCT03849118  ↩︎
  2. Zircaix® brand name is subject to final regulatory approval.  ↩︎